DexCom (NASDAQ:DXCM) Rating Lowered to Hold at StockNews.com

DexCom (NASDAQ:DXCM - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Saturday.

Several other equities analysts have also commented on the company. Stifel Nicolaus boosted their price target on DexCom from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, August 23rd. Raymond James reduced their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Sanford C. Bernstein lifted their price objective on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Finally, BTIG Research dropped their price objective on DexCom from $156.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Trading Down 0.2 %

DexCom stock opened at $70.35 on Friday. The stock has a market cap of $27.48 billion, a PE ratio of 42.13, a P/E/G ratio of 2.20 and a beta of 1.18. The stock has a 50-day moving average price of $69.85 and a 200 day moving average price of $95.92. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company's stock.

Hedge Funds Weigh In On DexCom

Hedge funds have recently made changes to their positions in the company. Acorn Financial Advisory Services Inc. ADV increased its holdings in shares of DexCom by 14.4% in the third quarter. Acorn Financial Advisory Services Inc. ADV now owns 14,399 shares of the medical device company's stock valued at $965,000 after purchasing an additional 1,814 shares during the last quarter. CWA Asset Management Group LLC purchased a new position in shares of DexCom during the third quarter worth $222,000. Comprehensive Financial Consultants Institutional Inc. boosted its position in shares of DexCom by 13.5% during the third quarter. Comprehensive Financial Consultants Institutional Inc. now owns 7,334 shares of the medical device company's stock worth $492,000 after buying an additional 874 shares during the period. AlphaCentric Advisors LLC purchased a new position in shares of DexCom during the third quarter worth $280,000. Finally, Quintet Private Bank Europe S.A. boosted its holdings in DexCom by 324.1% in the third quarter. Quintet Private Bank Europe S.A. now owns 4,105 shares of the medical device company's stock valued at $275,000 after purchasing an additional 3,137 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.